Health & Medicine Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health & Medicine Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Antibiotics
Licensing agreement reached for broad-spectrum antibiotic
October 27th, 2003
Peninsula Pharmaceuticals, Inc., and Takeda Chemical Industries, Ltd. (Osaka, Japan), have reached a licensing agreement for TAK-599, a broad-spectrum antibiotic currently being readied for clinical trials. Peninsula has obtained exclusive rights, including sublicense rights, to develop and market TAK-599 in all territories outside Japan; Takeda will manufacture the product for worldwide distribution. Financial terms of the agreement were not disclosed. TAK-599 is the newest member of the broad-spectrum cephalosporin class of antibacterials and displays excellent activity against gram-positive and gram-negative pathogens including...
Source: Health & Medicine Week (2003-10-27)
|
